Fortis Capital Advisors’s AbbVie ABBV Stock Holding History

Fortis Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.06M	Buy	16,124 +262	+2%	+$56.4K	0.46%	38
2026 Q1	$3.45M	Buy	15,862 +9,065	+133%	+$2.01M	0.45%	40
2025 Q4	$1.55M	Buy	6,797 +151	+2%	+$34.4K	0.23%	66
2025 Q3	$1.54M	Buy	6,646 +1,432	+27%	+$292K	0.24%	61
2025 Q2	$968K	Buy	5,214 +475	+10%	+$88.3K	0.17%	91
2025 Q1	$993K	Sell	4,739 -3,711	-44%	-$721K	0.2%	89
2024 Q4	$1.66M	Sell	8,450 -162	-2%	-$29.8K	0.57%	31
2024 Q3	$1.7M	Buy	8,612 +1,240	+17%	+$231K	0.57%	30
2024 Q2	$1.26M	Sell	7,372 -377	-5%	-$62.5K	0.46%	39
2024 Q1	$1.41M	Buy	7,749 +1,148	+17%	+$198K	0.59%	27
2023 Q4	$1.02M	Sell	6,601 -2,326	-26%	-$339K	0.55%	30
2023 Q3	$1.33M	Sell	8,927 -996	-10%	-$146K	0.85%	23
2023 Q2	$1.34M	Sell	9,923 -1,220	-11%	-$179K	0.78%	26
2023 Q1	$1.78M	Buy	11,143 +36	+0.3%	+$5.5K	0.95%	22
2022 Q4	$1.79M	Buy	+11,107	New	+$1.7M	1.07%	18

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fortis Capital Advisors's ABBV Position: Q2 2026 in Review

Fortis Capital Advisors increased its AbbVie (ABBV) stake by 1.7% in Q2 2026, buying an estimated $56.4K and bringing the position to 16,124 shares worth $4.06M. The position accounts for 0.46% of the portfolio, ranked #38.

Fortis Capital Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Fortis Capital Advisors held 16,124 shares of AbbVie worth $4.06M as of Q2 2026.
Fortis Capital Advisors bought 262 AbbVie shares in Q2 2026, an estimated $56.4K.
AbbVie made up 0.46% of Fortis Capital Advisors's portfolio in Q2 2026, its #38 holding.
Fortis Capital Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fortis Capital Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.